Nanjing Vazyme Biotech Co., Ltd.: history, ownership, mission, how it works & makes money

From its founding in 2012 by Dr. Cao Lin to its 2021 debut on the STAR Market under ticker 688105.SS, Nanjing Vazyme Biotech has rapidly scaled into a biotech force: certified to ISO 13485, expanding production lines in 2022, and launching a sensitive Alzheimer's blood test in 2024; today the company reports a workforce of 2,867 (Dec 2024), a market capitalization of about 8.19 billion CNY (Dec 11, 2025) and a stock price of 20.17 CNY (Dec 12, 2025, 52‑week range 19.28-27.50); Vazyme's commercial engine generated 346.18 million CNY in Q3 2025 and 1.34 billion CNY TTM revenue, building on 1.38 billion CNY in 2024 (up 7.15% year‑over‑year), while investing over 80 million USD in R&D to staff a global network of more than 3,000 scientists, operate a 25,000㎡ R&D center and a 64,000㎡ production base, offer over 500 final products, publish more than 2,000 papers (including over 260 in Cell/Nature/Science family journals), and deliver revenue per employee of 468.92K CNY as it pursues market expansion and deeper penetration in molecular diagnostics.

Nanjing Vazyme Biotech Co., Ltd. (688105.SS): Intro

• Founded: 2012 by Dr. Cao Lin in Nanjing; initial mission-affordable, efficient reagents for research.
• ISO & regulatory milestones: ISO 13485 certification achieved by 2021, aligning manufacturing quality with medical device standards.
• Public listing: IPO on the Shanghai STAR Market in 2021 (stock code 688105.SS).
• Production upgrades: 2022 expansion and modernization of cell- and protein-research reagent and instrument production lines.
• Clinical innovation: 2024 launch of a highly sensitive blood-test solution aimed at early Alzheimer's Disease detection.
• Expansion trajectory: through late 2025 Vazyme extended product portfolios and global distribution channels.

• Primary revenue streams:
  • Research reagents and consumables (bulk kits, enzymes, nucleic acid purification): core and highest-margin business.
  • Instruments and automation platforms: mid-to-long sales cycles, recurring revenue from consumables and service.
  • Clinical diagnostics & IVD solutions (including AD blood-test): higher regulatory barriers, higher ASPs and margins when adopted clinically.
  • OEM/contract manufacturing and reagent licensing: supplemental revenue and capacity utilization.
• Revenue characteristics:
  • Recurring revenue from consumables and kits drives predictable cash flow; instruments act as customer-locked entry points.
  • R&D investment focused on reagent chemistry, assay sensitivity and automation integration-supports product upgrades and new diagnostic launches.
  • Geographic expansion leverages domestic manufacturing base to pursue Asia, Europe and select global distributors.

• Listed entity: shares traded on Shanghai STAR Market under 688105.SS - public investors and institutional holders participate post-IPO.
• Founding and management ownership: founders and early investors commonly hold significant stakes typical of China biotech listings (founder/management + VC/PE pre-IPO holdings); public float expanded after 2021 listing.
• Governance: board and supervisory structure aligned with Chinese public-company norms, with emphasis on technology-driven strategy and regulatory compliance for clinical products.

• Vertical integration from enzyme and reagent chemistry to kit formulation and automation-reduces COGS and improves margin control.
• Ability to translate research reagents into clinical-grade IVD assays (e.g., AD blood test) leverages regulatory certifications attained since 2021.
• Scale-up capability following 2022 production upgrades supports higher-volume academic and industrial contracts.

Nanjing Vazyme Biotech Co., Ltd. (688105.SS): History

• Public listing: STAR Market, Shanghai Stock Exchange - ticker 688105.SS, enabling public ownership and capital raising.
• Founder leadership: Dr. Cao Lin serves as Chairman and General Manager, retaining major strategic influence.
• Workforce scale: 2,867 employees as of December 2024, reflecting R&D, manufacturing, sales, and regulatory teams.

• Product sales: core revenue from reagents, enzymes, kits, and consumables sold to academic, clinical, and industrial customers.
• Service & support: technical services, assay development, and custom reagent development for partners and clinical labs.
• Platform expansion: proprietary enzyme and library-prep platforms that drive recurring consumable purchases.
• Geographic channels: direct sales in China plus distribution partnerships for export markets.

• Mission: enable life‑science research and clinical testing through reliable molecular biology reagents and platforms.
• Priorities: deepen R&D (enzymes, kits), scale manufacturing capacity, regulatory approvals for clinical assays, and broaden international distribution.

Nanjing Vazyme Biotech Co., Ltd. (688105.SS): Ownership Structure

• Mission and values: lead biotechnology innovation, pursue highest product/service quality, create customer value, break foreign technical barriers, and advance the national and global biotech sectors.
• Core value: innovation - cumulative R&D investment exceeding 80 million USD to date.
• Quality commitment: certified to ISO 13485 standard for medical device quality management.
• Customer-centricity: product and service design focused on performance, reliability and diverse end-user needs.
• Continuous improvement: culture aimed at enhancing research efficiency and contributing to global biotech development.

• Product sales: majority of revenue derives from reagents, molecular kits (PCR, NGS library kits), enzymes and proprietary consumables sold to research institutions, hospitals, and diagnostic labs.
• Platform and instrument sales: complementary instruments and kits bundle to increase recurring consumable sales and customer stickiness.
• OEM and distribution partnerships: licensing, contract manufacturing and distribution agreements expand market access domestically and internationally.
• R&D services and collaborations: partnerships with academic and clinical organizations for bespoke assay development and co‑development revenue.

• Public shareholders: free-float holders on SSE STAR Market alongside strategic shareholders and management holdings typical for Chinese biotech IPOs.
• Governance: board and supervisory structure aligned with PRC listed company requirements; management emphasizes R&D reinvestment and scaling manufacturing quality.
• Strategic objective: reduce reliance on foreign core technologies and elevate domestic capabilities in molecular diagnostics and life‑science reagents.

Nanjing Vazyme Biotech Co., Ltd. (688105.SS): Mission and Values

• Mission: Provide robust, reproducible molecular tools and diagnostic solutions that shorten research cycles and enable rapid, accurate clinical testing.
• Core values: scientific excellence, customer focus, product quality, continuous R&D investment, and open collaboration.
• Strategic focus: expand global market access, deepen partnerships with academic and clinical institutions, and accelerate platform-driven product development.

• Global R&D network staffed by over 3,000 scientists, experts, bio‑technicians, medical specialists, engineers, and software developers.
• Significant capital and infrastructure commitment - over 80 million USD invested in R&D projects, personnel, and equipment; a 25,000㎡ R&D center and a 64,000㎡ production base.
• Broad product portfolio: more than 500 final products, including nucleic acid extraction reagents, molecular biology reagents, enzymes, and diagnostic kits (notably COVID‑19 detection kits).
• Scientific output and credibility: over 2,000 published papers in top academic journals, including more than 260 papers in Cell, Nature, Science and their sub‑journals (as of November 2021).
• Deep collaboration network: partnerships with academic institutions, clinical laboratories, biopharma companies and domestic enterprises to co-develop products and provide customized technical solutions and services.

• Revenue streams:
  • Product sales - reagents, kits, enzymes, consumables to research institutions, clinical labs, and OEM customers.
  • Service and support - technical consulting, assay validation, and customization for industrial and clinical partners.
  • Strategic collaborations and licensing - co-development agreements and technology transfers with domestic and international partners.

• High-margin consumable sales: recurring reagent and kit purchases from research labs and clinical sites provide steady revenue and high gross margins typical of molecular reagents.
• Volume-driven manufacturing: large production base (64,000㎡) enables economies of scale for global distribution and OEM contracts.
• Product diversification: broad product lines (500+) reduce revenue concentration risk and allow cross‑sell/up‑sell to existing customers.
• Service-led differentiation: technical support, assay customization, and clinical validation services strengthen customer retention and create additional revenue per account.
• Collaborative development: joint projects and licensing deals with domestic enterprises and academic partners accelerate time‑to‑market for new assays and expand addressable markets.

• Academic collaborations: co-development, method validation, and joint publications that both validate products and enhance scientific reputation.
• Clinical lab partnerships: deployment of diagnostic kits and workflow integration in hospital and independent lab networks.
• Industrial alliances: strategic cooperative relationships with domestic enterprises to co-develop new products and meet evolving market demands.

Nanjing Vazyme Biotech Co., Ltd. (688105.SS): How It Works

• Primary revenue streams: proprietary reagents and kits (PCR enzymes, qPCR kits, library prep, sequencing reagents), diagnostic consumables, benchtop instruments, and technical service/support.
• Go-to-market channels: direct sales force to hospitals and research institutions, distributor partnerships for international markets, and e-commerce/B2B portals for smaller customers.
• R&D-driven product expansion: continuous pipeline of improved chemistries and kits to capture recurring consumable demand from installed base of instruments and workflows.

• How the economics work: recurring consumables (reagents and kits) provide high-margin, repeatable sales; instruments and diagnostic platforms drive upfront sales and lock-in for consumable streams.
• Profit levers: product mix shift toward higher-margin proprietary chemistries, scale efficiencies in manufacturing, and international market expansion through distributors.
• Operational efficiency indicator: revenue per employee of 468.92K CNY signals capital-light commercial scaling relative to manufacturing footprint.

Nanjing Vazyme Biotech Co., Ltd. (688105.SS): How It Makes Money

• Core revenue drivers: molecular diagnostic kits, enzymes & reagents, sequencing-related products, and laboratory instrumentation.
• Recurring consumable sales (reagents and kits) create steady margins and customer stickiness.
• Platform licensing and OEM partnerships expand addressable market and generate non‑product revenue.
• Clinical and research service offerings provide higher‑margin, project-based income and market validation.

• R&D intensity: sustained investment in product pipeline to maintain technological leadership and expand diagnostic panels.
• Geographic expansion: growing export and distributor networks to convert domestic leadership into global market share.
• Financial outlook: current valuation and revenue base support continued scaling, though stock price volatility (52‑week band) reflects market sensitivity to product approvals and sales execution.